Seroatlas · Human Serome Atlas

TRABD2A

Metalloprotease TIKI1

Also known as: C2orf89, TIKI1, TIKI1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86V40
Gene: TRABD2A
Ensembl: ENSG00000186854
Chromosome: 2
Canonical length: 505 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Enables Wnt-protein binding activity and metalloendopeptidase activity. Involved in negative regulation of Wnt signaling pathway and proteolysis. Located in organelle membrane and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

505 residues, UniProt reviewed canonical sequence.

>Q86V40|TRABD2A
     1  MSPWSWFLLQ TLCLLPTGAA SRRGAPGTAN CELKPQQSEL NSFLWTIKRD PPSYFFGTIH
    61  VPYTRVWDFI PDNSKEAFLQ SSIVYFELDL TDPYTISALT SCQMLPQGEN LQDVLPRDIY
   121  CRLKRHLEYV KLMMPLWMTP DQRGKGLYAD YLFNAIAGNW ERKRPVWVML MVNSLTEVDI
   181  KSRGVPVLDL FLAQEAERLR KQTGAVEKVE EQCHPLNGLN FSQVIFALNQ TLLQQESLRA
   241  GSLQIPYTTE DLIKHYNCGD LSSVILSHDS SQVPNFINAT LPPQERITAQ EIDSYLRREL
   301  IYKRNERIGK RVKALLEEFP DKGFFFAFGA GHFMGNNTVL DVLRREGYEV EHAPAGRPIH
   361  KGKSKKTSTR PTLSTIFAPK VPTLEVPAPE AVSSGHSTLP PLVSRPGSAD TPSEAEQRFR
   421  KKRRRSQRRP RLRQFSDLWV RLEESDIVPQ LQVPVLDRHI STELRLPRRG HSHHSQMVAS
   481  SACLSLWTPV FWVLVLAFQT ETPLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRABD2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 40 nTPM

Expression across tissuesHPA

Tissue

rectum: 40 nTPM
ovary: 38 nTPM
colon: 38 nTPM
lymph node: 11 nTPM
small intestine: 10 nTPM
appendix: 8.4 nTPM

Single-cell type

early spermatids: 610 nCPM
epicardial cells: 448 nCPM
late spermatids: 390 nCPM
late primary spermatocytes: 269 nCPM
enteric stem cells: 198 nCPM
plasma cells: 161 nCPM

Immune cell

naive CD4 T-cell: 72 nTPM
naive CD8 T-cell: 46 nTPM
memory CD4 T-cell: 34 nTPM
T-reg: 24 nTPM
total PBMC: 13 nTPM
memory CD8 T-cell: 12 nTPM

Brain region

thalamus: 8.6 nTPM
cerebral cortex: 7.6 nTPM
midbrain: 5.9 nTPM
basal ganglia: 4.6 nTPM
amygdala: 3.6 nTPM
white matter: 3.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.28
gnomAD pLI: 0
gnomAD missense Z: 0.45
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRABD2A as an antibody target. Whether an autoantibody or antibody against TRABD2A could matter depends on whether native TRABD2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRABD2A is annotated at the cell surface, where native TRABD2A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TRABD2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...